Yao Wang, Chengxia Jiang, Xiaolin Dong, Mingwei Chen, Qin Gu, Lihui Zhang, Yanqin Fu, Tianrong Pan, Yan Bi, Weihong Song, Jing Xu, WeiPing Lu, Xiaodong Sun, Zi Ye, Danli Zhang, Liang Peng, Xiang Lin, Wei Dai, Quanren Wang, Wenying Yang
AIM: This study assessed the efficacy and safety of co-administering retagliptin and henagliflozin versus individual agents at corresponding doses in patients with type 2 diabetes mellitus who were inadequately controlled with metformin. METHODS: This multicentre, phase 3 trial consisted of a 24-week, randomized, double-blind, active-controlled period. Patients with glycated haemoglobin (HbA1c) levels between 7.5% and 10.5% were randomized to receive once-daily retagliptin 100 mg (R100; n = 155), henagliflozin 5 mg (H5; n = 156), henagliflozin 10 mg (H10; n = 156), co-administered R100/H5 (n = 155), or R100/H10 (n = 156)...
April 15, 2024: Diabetes, Obesity & Metabolism